Xenetic Biosciences’ (XBIO) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note released on Friday,Weiss Ratings reports.

Xenetic Biosciences Stock Performance

XBIO stock opened at $4.01 on Friday. The firm has a market cap of $6.18 million, a PE ratio of -2.01 and a beta of 2.42. The firm’s fifty day moving average is $3.69 and its 200 day moving average is $3.32. Xenetic Biosciences has a one year low of $2.20 and a one year high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.19. The company had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.48 million. Xenetic Biosciences had a negative net margin of 126.08% and a negative return on equity of 54.56%. Research analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC grew its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,259 shares of the company’s stock after purchasing an additional 4,593 shares during the quarter. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.